# OMOP2OBO: Semantic Integration of Standardized Clinical Terminologies to Power Translational Digital Medicine Across Health Systems

PRESENTER: Tiffany J. Callahan

# Background

Despite significant progress in biobanking, translational use of electronic health records (EHRs) remains largely aspirational due to its disconnectedness from biomedical knowledge. Open Biomedical Ontologies (DRos) provide detailed representations of biological domains, are logically verifiable using description logics, and can be easily integrated with basic science data and clinical research (Figure 1).

## MAPPING CHALLENGES

Limitations of existing work in this domain:

clinical terminologies and OBO ontologies.

- Focused on specific diseases and biological domains
   Largely limited to one-to-one mappings
   Rarely include external validation
- Existing algorithms cannot automatically capture complex biological semantics underlying clinical concepts

biological semantics underlying clinical concepts

GOAL: Develop OMOP2OBO, the first health system-wide integration and alignment between OMOP standardized

## Methods

- OMOP-normalized Children's Hospital Colorado EHR data.
- OBOs were selected by domain experts and included diseases, phenotypes, anatomical entities, cell types, organisms, small molecules, vaccines, and proteins.
- Mappings were performed using the pipeline in Figure 2.
- 20% of the most challenging mappings were verified by a panel of clinical and molecular domain experts.
- Mapping generalizability was assessed by comparing the coverage of mapped concepts to 2 independent EHRs.

## Result

- 20,850 condition concepts were mapped to 4,661 phenotypes and 3,614 diseases (Figure 3).
- 1,574 of drug ingredient concepts were mapped to 1,422 chemicals, 91 proteins, 39 organisms, and 54 vaccines.
   11,072 measurement results mapped to over 920
- phenotypes, 25 anatomical entities, 27 cell types, 338 chemicals, 194 organisms, and 113 proteins.

# Domain expert agreement was found for 91.6% of

- measurements, 75.8% of ingredients, and 73.8% of conditions.

  80-92% for conditions, 91-96% for ingredients, and 50-55%
- 80-92% for conditions, 91-96% for ingredients, and 50-55% for measurement concepts on EHR from two independent health systems revealed.

### Discussion

OMOP2OBO is the first health system-wide integration of OMOP clinical terminology concepts and OBO biomedical ontologies.

### FUTURE WORK

We are currently working on expanding the mapping provenance to include mechanisms of actions and conducting an expanded coverage study, using data from the OHDSI Concept Prevalence Study.

Aligning molecular data to **OMOP** standardized terminologies will support biologically meaningful analysis of EHR data. which can be achieved by integrating knowledge from **biomedical** ontologies.





Take a picture to download the full paper





domains (i.e. conditions, drug ingredients, measurements, and immunizations) can be linked with biological mechanisms of human disease using biomedical ontologies.



mapping strategies: Automatic and manual. The automatic approach uses all ONO? standard concepts, ancestors, labels, and synonyms and all ontology labels, synonyms, definitions, and database cross-references.




Figure 3. Mapped concepts for each ontology by dinical domain (i.e. conditions, drug ingredients, and measurements) and mapping category. HPO (Human Phenotype Ontology), MONDO (Mondo disease Ontology), OHEBI (Chemical Emities of Biological Interest), PR (Protein Ontology), NGSITaxon (NCBI Organism Taxonomy), VO (Vaccine Ontology), USESON (User-Anatomy) (Notology), CL (Cell Ontology)

#### AUTHORS:

Tiffany J. Callahan, MPH<sup>1</sup>, Jordan M. Wyrwa, DO<sup>1</sup>, Nicole A Vasilevsky, PhD<sup>2</sup>, Peter N. Robinson, MD, PhD<sup>3</sup>, Melissa A Haendel, PhD<sup>4</sup>, Lawrence E. Hunter, PhD<sup>1</sup>, Michael G. Kahn, MD, PhD<sup>1</sup>

<sup>1</sup>University of Colorado Anschutz Medical Campus, Aurora, CO, USA; <sup>2</sup>Oregon Health Sciences University, Portland, OR, USA; <sup>3</sup>The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; <sup>4</sup>Oregon State University, Corvallis, OR, USA





